Ardena announced a expansion of its bioanalytical services in the Netherlands, including a new bioanalytical lab at Ardena’s Pivot Park facility in Oss and new GLP capabilities in Assen.
Naobios and Sumagen Canada Inc, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, announced the production of the HIV-1 vaccine candidate at bench scale.
This acquisition will significantly enhance Ardena’s capabilities in downstream late-stage and small-scale commercial manufacturing of oral drug products.
medac group reported a series of productive and insightful meetings with both current and potential business partners during this year’s CPHI Congress in Milan.
Exothera, a GMP-certified CDMO offering a complete range of services for viral vectors, RNA therapeutics, and vaccines, has announced the appointment of a new CEO, Cédric Volanti.
Thermo Fisher Scientific will showcase its latest innovations enabling the molecule-to-medicine journey and host a series of sessions that feature industry developments during CPHI Milan 2024.
The CPHI Annual Industry Survey reveals that the pharma sector is on the cusp of a major shift, with approvals for complex molecules expected to outpace those for small molecules for the first time.
David Blanco, Industrial BD & CDMO director, Suanfarma, shares how the pharma industry can enhance innovation by combining biofermentation and chemical synthesis, while highlighting the importance of technology transfer for implementation of both.
Ahead of CPHI Milan, EPM spoke to Thierry Van Nieuwenhove, CEO of Quotient Sciences, to explore how the company is innovating to meet the growing demand for personalised medicine through AI, partnerships and meeting sustainability goals.
Recipharm and Exela Pharma Sciences announced an exclusive strategic alliance aimed at enhancing sterile manufacturing capabilities in the United States.
PCI Pharma Services, (“PCI”) a global contract development and manufacturing organisation (CDMO) focused on biopharma’s most complex therapies, is investing more than $365 million in infrastructure.
Within the new group of companies, Konapharma now complements the services of packaging company Allpack and Rhenochem, a family-owned company with decades of extensive experience and expertise in the global pharmaceutical industry.
